QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.43    
    


[IMMUNICON
LOGO] 


September 16,
2002 


Paul
A. Liberti, Ph.D.

Unit 305

7225 Pelican Bay Blvd.

Naples, FL 34108 


Re: Consulting Agreement ("Agreement") with Immunicon Corporation effective January 1, 2000, through January 1, 2002, as amended and extended to
September 20, 2002  


Dear
Dr. Liberti: 


Immunicon
Corporation wishes to further extend and amend this Agreement as provided below. 


The Agreement, as amended and extended to September 20, 2002, will be further extended and amended, effective September 20, 2002, as
follows:


Paragraph 2
is hereby replaced in its entirety with the following: 


The
Term of this Consulting Agreement (the "Term") shall commence as of September 20, 2002 (the "Effective Date") and shall continue through December 31, 2003, unless this Agreement is
sooner terminated in accordance with the provisions of Section 8 hereof, and shall be automatically renewed under the same terms and conditions as set forth herein, for successive
one-year periods thereafter, unless terminated by either Immunicon or Consultant by the giving of written notice of termination to the other party at least thirty (30) days prior to
the end of any such one-year extension. 


The
first sentence of Paragraph 3 is amended to read as follows: 


During
the Term, Consultant agrees to consult with, advise and assist Immunicon in the Field, and in accordance with the specific duties and responsibilities set forth in Attachment A. 


During this further extension of the Term referred to above, the following amendments will apply to Attachment A of this Agreement:



The
paragraph entitled "Field and Duties" is amended to read: 


Consultant
will provide advice and assistance to Immunicon broadly in the field of analytical chemistry and methods and general business matters, serve as a member of the Scientific Advisory Board of
Immunicon, lead the Immunicon grant applications program, consult on Immunicon's intellectual property program and assist Immunicon personnel with respect to patent preparation and prosecution and
other Intellectual property matters as requested, provide advice and consultation as Immunicon's Chief Technical Officer, and assist in identifying niche opportunities for Immunicon's magnetic
particle/separation technologies. In particular, Consultant shall devote substantial effort to identifying and assisting in the acquiring of "non-traditional" funding for Immunicon, such
as, without limitation, governmental and other institutional grants. 


The
paragraph entitled "Compensation" is amended by adding at the end thereof the following: 


Consultant
additionally will be compensated by being paid a cash bonus of five percent (5%) of the total net direct cash flow to Immunicon and actually received by Immunicon, resulting from
Consultant's identification and acquisition of the "non-traditional" funding as set forth above; provided that if such funding or any portion thereof is provided to another institution or
entity but is determined by Immunicon's management to be directly of business benefit to Immunicon, Consultant will be paid two and one-half percent (21/2%) of the total net
amount of such funding actually received by the other institution or entity. The total amount of the cash bonus paid to Consultant in each twelve-month period of the Term of this Agreement, regardless
of the amount of "non-traditional" funding received 








by
Immunicon or the above-mentioned institutions or entities, will not exceed seventy five thousand dollars ($75,000). Consultant will also be reimbursed his ordinary, reasonable and necessary
business expenses, such as airfare, rental car and hotel expenses, connected with his efforts in identifying and acquiring such "non-traditional" funding on behalf of Immunicon, provided
that any portion of such expenses totaling more than $4500 in any twelve-month period of the Term of this Agreement shall be approved in advance by Immunicon prior to being reimbursed. 


It
is understood and agreed that all of the remaining terms and conditions of the Agreement which are not amended as set forth above shall remain unchanged and in full force and effect during this
extension period and any renewal thereof. 


If
you are in agreement with the foregoing, please so indicate by signing both copies of this letter where indicated below, and return one signed copy to me. 



	Sincerely,	 	Accepted and Agreed:
	IMMUNICON CORPORATION	 	Paul A. Liberti, Ph.D.
	

/s/  EDWARD L ERICKSON      
	
 	

/s/  PAUL A. LIBERTI      

	Edward L. Erickson

Chairman, President and CEO	 	Date of Signature: 9/23/02.











QuickLinks



Exhibit 10.43